男女2型糖尿病合并非酒精性脂肪性肝病患者血清性激素和甲状腺激素水平变化分析*

doi:10.3969/j.issn.1672-5069.2025.05.013

Abstract

Abstract: Objective The aim of this study was to investigate changes of serum sex hormones and thyroid hormones in patients with type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Methods The general clinical materials were collected from 100 patients with T2DM and NAFLD, and 100 patients with T2DM in our hospital between January 2021 and December 2023. Serum testosterone (T), estradiol (E2), follicle stimulating hormone (FSH) and luteinizing hormone (LH), as well as serum free triiodothyronine (FT3), free tetraiodothyronine (FT4) and thyroid stimulating hormone (TSH) were detected by chemiluminescence immunoassay. The risk factors of NAFLD in patients with T2DM were analyzed by multivariate Logistic regression analysis. Results Waist circumference (WC), body mass index (BMI), serum E2 and TSH levels in male patients with T2DM and concomitant NAFLD were (92.4±11.2)cm, (26.5±2.5)kg/m², (23.5±7.8)pg/mL and (3.1±0.5)mU/L, all significantly higher or greater than [(87.7±9.4)cm, (24.6±2.2)kg/m², (17.2±5.6)pg/mL and (2.1±0.4)mU/L, respectively, P＜0.05], while serum T level was (3.5±1.1)ng/mL, significantly lower than [(4.6±1.5)ng/mL, P＜0.05] in patients with T2DM; multivariate Logistic regression analysis showed that serum T, E2 and TSH levels were all the independent risk factors for NAFLD existence in patients with T2DM(P＜0.05); WC, BMI and serum TSH level in female patients with T2DM and NAFLD were(81.6±8.0)cm, (26.7±2.3)kg/m² and (3.3±0.6)mU/L, all significantly greater or higher than [(77.3±7.1)cm, (24.4±2.1)kg/m² and (2.5±0.5)mU/L, respectively, P＜0.05], while serum E2 and FSH levels were (20.4±6.5)pg/mL and (59.8±11.5)mIU/mL, both significantly lower than [(26.3±7.9)pg/mL and (71.7±13.8)mIU/mL, respectively, P＜0.05] in patients with T2DM; multivariate Logistic regression analysis demonstrated that serum E2, FSH and TSH levels were all the independent risk factors for NAFLD existence in patients with T2DM(P＜0.05). Conclusion Sex hormones and thyroid hormones are obviously abnormal in both male and female patients with T2DM and NAFLD, and the in-depth study might clarify the mechanism of the entity.

Key words: Non-alcoholic fatty liver disease, Type 2 diabetes mellitus, Sex hormone, Thyroid hormone

Chen Ruiting, Yuan Kemin, Peng Xiaolong. Changes of serum sex hormones and thyroid hormones in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(5): 691-694.

References

[1] Christensen MB, Gæde P, Hommel E, et al. Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes. Diabetes Metab, 2020, 46(1):61-65.
[2] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023, 77(5):1797-1835.
[3] Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from theAmerican heart association. Arterioscler Thromb Vasc Biol, 2022, 42(6):e168-e185.
[4] Han X, Zhang X, Liu Z, et al. Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus. J Diabetes, 2024, 16(5):e13564.
[5] Ge S, Zheng Y, Du L, et al. Association between follicle-stimulating hormone and nonalcoholic fatty liver disease in postmenopausal women with type 2 diabetes mellitus. J Diabetes, 2023, 15(8):640-648.
[6] Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, et al. Sex hormone-dependent physiology and diseases of liver. Int J Environ Res Public Health, 2020, 17(8):2620.
[7] 方山山,杜明桥,王玥.垂体功能减退症患者非酒精性脂肪性肝病发生情况及其相关激素水平变化.实用肝脏病杂志,2023,26(4):504-507.
[8] Sun M, Yu L, Zhao X, et al. Correlation between thyroid hormone sensitivity and diabetic peripheral neuropathy ineuthyroid patients with type 2 diabetes mellitus. Sci Rep, 2024, 14(1):19603.
[9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版).中华糖尿病杂志,2021,13(4):315-409.
[10] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志,2024,27(4): 494-510.
[11] 李敏,张丽,曾艾,等.2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化检出率及预测因素分析.实用肝脏病杂志,2024,27(2):193-197.
[12] Chew NWS, Ng CH, Tan DJH, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab, 2023, 35(3):414-428,e3.
[13] Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol, 2021, 17(8):484-495.
[14] Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol, 2023, 78(3):471-478.
[15] Dong J, Liu C, Lu J, et al. The relationship between sex hormone-binding protein and non-alcoholic fatty liver disease using Mendelian randomisation. Eur J Clin Invest, 2024, 54(1):e14082.
[16] Bourebaba N, Ngo T, Śmieszek A, et al. Sex hormone binding globulin as a potential drug candidate for liver-related metabolic disorders treatment. Biomed Pharmacother, 2022, 153:113261.
[17] Weng C, Shao Z, Xiao M, et al. Association of sex hormones with non-alcoholic fatty liver disease: An observational and Mendelian randomization study. Liver Int, 2024, 44(5):1154-1166.
[18] Wei Y, Liu J, Wang G, et al. Sex differences in the association between adipose insulin resistance and non-alcoholic fatty liver disease in Chinese adults. Biol Sex Differ, 2023, 14(1):69.
[19] Phan H, Richard A, Lazo M, et al. The association of sex steroid hormone concentrations with non-alcoholic fatty liver disease and liver enzymes in US men. Liver Int, 2021, 41(2):300-310.
[20] Kim D, Manikat R, Cholankeril G, et al. Endogenous sex hormones and nonalcoholic fatty liver disease in US adults. Liver Int, 2024, 44(2):460-471.
[21] Chiovato L, Magri F, Carlé A. Hypothyroidism in context: where we've been and where we're going. Adv Ther, 2019, 36(Suppl 2):47-58.
[22] Mavromati M, Jornayvaz FR. Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD. Int J Mol Sci, 2021, 22(23):12797.
[23] D'Ambrosio R, Campi I, Maggioni M, et al. The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD). PLoS One, 2021, 16(4):e0249614.

Changes of serum sex hormones and thyroid hormones in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Lingyun, Mei Ying, Chen Mengxue, et al. Diagnostic efficacy of non-alcoholic fatty liver diseases by quantitative CT measurement in individuals for physical examination [J]. Journal of Practical Hepatology, 2025, 28(5): 687-690.
[2]	Zhang Lei, Wang Yaru, Li Huiping, et al. Clinical observation of semaglutide and metformin combination in treatment of patients with type 2 diabetes mellitus and concomitant nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(5): 699-702.
[3]	Wu Xiaoyu, Shi Lu, Shou Mengyuan, et al. 1990-2021 disease burden of non-alcoholic fatty liver disease in China and its trends from 2020 to 2040 [J]. Journal of Practical Hepatology, 2025, 28(5): 707-710.
[4]	Hou Yu, Zou Guangxu, Zhao Yingpeng. A metabolomics perspective: unveiling two types of fatty liver diseases [J]. Journal of Practical Hepatology, 2025, 28(4): 485-488.
[5]	Ni Shenjue, Wang Pengfei, Huang Yanhua, et al. Changes of serum maresin-1, omentin-1 and microRNA-125b, and their correlation to liver inflammation and fibrosis in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(4): 533-536.
[6]	Zhang Shuwei, Zhang Huijuan, Zhou Jie. Clinical observation of rosiglitazone and metformin combination in the treatment of patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2025, 28(4): 545-548.
[7]	Wang Xintian, Yao Lan, Xu Ke, et al. Serum iron, ferritin light chain, unsaturated iron binding capacity and transferrin levels in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(4): 549-552.
[8]	Yang Hao, Yi Bo, Liu Hongyan. Clinical implications of serum IFN-α and IFN-β levels in patients with T2DM and metabolic-associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(4): 557-560.
[9]	Lu Yifan, Chen Hao, Huai Jiaxian, et al. Hashimoto's thyroiditis and nonalcoholic fatty liver disease:contingency or causality? [J]. Journal of Practical Hepatology, 2025, 28(3): 326-329.
[10]	Xu Lingling, Lu Yuan, Zheng Yanchai, et al. Improvement of liver function tests by oral bicyclol in patients with type 2 diabetes mellitus and nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(3): 358-361.
[11]	Qin Hao, Fang Chunhua, He Jing, et al. Comparison of diagnostic performance of six non-invasive evaluation scores for type 2 diabetes mellitus with metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 366-369.
[12]	Wen Dachao, Zhang Qiuping, Shi Ling. Short-term observation of acupoint application and exercise in the treatment of patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 370-373.
[13]	Wang Xintian, Kang Xiaobo, Wu Xia, et al. Changes of serum osteocalcin,β-I type collagen carboxy-terminal peptide and angiotensin levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2025, 28(3): 378-381.
[14]	Zeng Ai, Wang Cong, Li Min, et al. Diagnostic performance of shear wave elastography and APRI combination in predicting significant liver fibrosis in patients with type 2 diabetes mellitus and NAFLD [J]. Journal of Practical Hepatology, 2025, 28(3): 382-385.
[15]	Liu Qianqian, Duan Zhijiao, Chen Ping. Non-invasive assessment of liver fibrosis in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 477-480.